peramivir (rapivab) Report issue

Small molecule Approved FDA Fast Track FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor. Rapivab (peramivir injection) is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days. Efficacy of Rapivab is based on clinical trials in which the predominant influenza virus type was influenza A and a limited number of subjects infected with influenza B virus were enrolled. Since influenza viruses change over time emergence of resistance substitutions could decrease drug effectiveness. Other factors such as changes in viral virulence might also diminish clinical benefit of antiviral drug. Efficacy could not be established in patients with serious influenza requiring hospitalization.   NCATS

Chemistry

  • SMILES: O.O.O.CCC(CC)[C@H](NC(=O)C)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(=N)N)C(=O)O
  • InChIKey: RFUCJKFZFXNIGB-ZBBHRWOZSA-N
  • Mol. Mass: 382.46
  • ALogP: -0.14
  • ChEMBL Molecules:
    peramivir  
    peramivir  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$35.4395
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(1-acetamido-2-ethyl-butyl)-4-guanidino-2-hydroxy-cyclopentane-1-carboxylic acid | 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid | bcx1812 | bcx 1812 | bcx-1812 | peramavir | peramivir | peramivir hydrate | rapiacta | rapivab | rwj270201 | rwj 270201 | rwj-270201

Organizations (56)

Research & Development (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Influenza, Human

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Cough (Phase 3)

Fatigue (Phase 3)

Fever (Phase 3)

Headache (Phase 3)

Influenza, Human (Phase 4)

Myalgia (Phase 3)

Nasal Obstruction (Phase 3)

Pharyngitis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 56

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue